The companAstraZeneca’sonday that LONDON — AstraZeneca’s green light in the U.S. — and has a troubled rollout.against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United States. The study comprised more than 30,000 volunteers, of whom two-thirds were given the vaccine while the rest got dummy shots. AstraZeneca said its experts did not identify any safety concerns related to the vaccine, including finding no increased risk of rare identified in Europe. AstraZeneca’saZeneca’s vaccine has been authorized in more than 50 countries, but it has not yet been given the
In a statement,had a 79% efficacy rate at preventing symptomatic COVID-19 and was 100% effective in stopping severe disease and hospitalization. However, it has not yet published complete data. Investigators said the across all ages, including older people — something previous studies in other countries had failed to establish. Two doses of the four” weeks apart. “These findings reconfirm previous “ults observed,” said Ann Falsey of the University of Rochester School of Medicine, who helped. “It’sthe trial. “It’s exciting to see similar efficacy results in people over 65 for”the first time.”
The company revealing efficacy data and a picture being authorized in the U.S. has been about a month.is a pillar of a U.N.-backed project known as COVAX to get to poorer countries. It has also become a vitalcountries’uropean countries’ efforts to boost their sluggish . The early findings from the U.S. study are just one set of information AstraZeneca must submit to the Food and Drug Administration. An FDA advisory committee will publicly debate the evidence behind the shots before the agency emergency vaccine use. In the past, the time between a
Julian Tang, a virologist at the University of Leicester who was not connected to the study, described t”e vaccine”s results as “good” news”. “The earlier U.K., Brazil, and South Africa trials had a more variable and inconsistent. It was thought that the U.S. on this basis, but now the U.S. clinical trial has confirmed the efficacy of this in their own clinical” trials,” he said. Scientists have been awaiting the results of the U.S. study in hopes it will clear up some confusion about how well the shots , particularly in older people. Previous the vaccine was effective in younger populations, but no reliable data proved its efficacy in those over 65, often those most vulnerable to COVID-19.
Britain first authorized the vaccine based on partial results from testing in the United Kingdom, Brazil, andwere about 70% effective. But those results were clouded by a manufacturing mistake that led some participants to get just a half dose in their first shot — an the researchers dididn’tmmediately acknowledge. Then came more questions about how well the before the second dose. Some European countries, including Germany, France, and Belgium, initially withheld the shot from older adults and only reversed their decisions after new data suggested offering seniors protection.
AstraZeAstraZeneca’se development was rocky in the U.S., too. Last fall, the Food and Drug Administration suspended the companies for an unusual six weeks as frustrated regulators sought information about some neurologic complaints reported in Britain; ultimately, there was no evidence the vaccine was to blame. , more than a dozen countries, mainly in Europe, temporarily suspended their use of the AstraZeneca shot after reports it was linked to blood clots. On Thursday, the European Medicines Agency concluded after an investigation that the but could not rule out that it was connected to two scarce types of nuggets. It recommended adding a to the vaccine’svaccine’s
It’s no.t It’s off for such rare problems to crop up as vaccines are rolled out since trials typically look at tens of thousands of people, and some issues are only seen once the shot is used in. France, Germany, Italy, and other countries resumed their trial on Friday, with senior politicians rolling up their sleeves to show the . AstraZeneca said it would continue analyzing U.S. data before submitting it to the FDA in the .
It said the data would also soon be published in a peer-reviewed journal. Theis what scientists call a “viral v”ctor” vaccine”. The shots are made with a harmless, cold chimpanzees. It acts like a Trojan horse to carry the spikeprotein-protein’ss material into the body,producings some harmless protein. That primes the to fight if the real virus comes along. Two other companies, Johnson & Johnson and China’s China’s Biologics, make using the same technology but different cold viruses. Neergaard reported from Washington.